Sign up Australia
Proactive Investors - Run By Investors For Investors

CymaBay Therapeutics' shares shoot up on phase 2 data for liver drug

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC)
CymaBay Therapeutics' shares shoot up on phase 2 data for liver drug
Primary biliary cholangitis (PBC) is a life-threatening and life-limiting chronic cholestatic liver disease

Shares in CymaBay Therapeutics Inc (NASDAQ:CBAY) rose over 25% to $7.08 on Monday on positive phase 2 trial results.

The results were from the ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting chronic cholestatic liver disease.

Seladelpar is in development for the treatment of liver diseases PBC and Nonalcoholic steatohepatitis (NASH).

After sharing preliminary results from this study, the FDA has agreed to allow continuation of seladelpar treatment beyond six months for the 5 mg and 10 mg doses, the group revealed.

"The data emerging from this study are impressive and support our hypothesis that lower doses of seladelpar than previously studied retain strong efficacy without raising a concern with transaminase elevations," said Professor Gideon Hirschfield, Centre for Liver Research at the University of Birmingham, UK

"We also see that seladelpar activity is not associated with drug-induced itch, an important benefit for patients with PBC. If these results are maintained over longer periods, we think that seladelpar could offer patients significant advantages over existing treatments," he added.

Giles_55af4ddca6481.jpg


Register here to be notified of future CBAY Company articles
View full CBAY profile View Profile

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
Netscientific has its thumbs in a few clinical pies
April 01 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms
Lab.jpg
April 05 2017
The share placing follows a period of expansion that has seen it make two major acquisition

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use